Method for treating HCV

US10286029B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Walid M. Awni · Libertyville, US
• Barry M. Bernstein · Mequon, US
• Andrew L. Campbell · Lake Forest, US
• Sandeep Dutta · Waukegan, US
• Chih-Wei Lin · Hsinchu, TW
• Wei Liu · Mundelein, US
• Rajeev M. Menon · Buffalo Grove, US
• Thomas J. Podsadecki · Chicago, US
• Tianli Wang · Lake Bluff, US
• Sven Mensing · Mannheim, DE

Key dates

• Filing date: Apr 1, 2015
• Grant date: May 14, 2019
• Expiry date: Apr 1, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.